Marc Gurwith, MD, JD: A Double-Blind Ascending Dose Placebo-Controlled Phase 2a Study of ABP-671, a Novel, Potent and Selective URAT1 Inhibitor, in Patients with Gout or Hyperuricemia

Poster Presenter: Marc Gurwith, MD, JD, Chief Medical Officer, Atom Bioscience

Poster Title: A Double-Blind Ascending Dose Placebo-Controlled Phase 2a Study of ABP-671, a Novel, Potent and Selective URAT1 Inhibitor, in Patients with Gout or Hyperuricemia

Ignite Session 4B
Sunday, November 13 | 10:05–10:10 a.m. ET | Center City Stage
All ACR Convergence 2022 poster presentations are available on demand to registered meeting participants through October 31, 2023.

What is your poster about?
The poster summarizes the first clinical study of ABP-671 in the treatment of gout. Gout patients received different doses of ABP-671 or placebo, given either once daily or split into bid dosing over a one-month period. The dose was increased from 2 mg to 4 mg to 8 mg total daily dose sequential groups.

Why did you decide to investigate this topic?
There is a clear need for better uric acid-lowering therapy for gout patients, and pre-clinical studies confirmed that ABP-671 was both safe and effective at uric acid lowering.

What are you working on next related to this research?
Plans are being finalized for a larger phase 2b study where gout patients will receive different doses of ABP-671, allopurinol, or placebo over a six-month period. This will be followed by confirmatory placebo-controlled phase 3 studies.

What excites you most about your work?
Current gout therapy is limited, with no truly satisfactory treatment. ABP-671 appears to have the potential to become a broadly effective and safe treatment for gout patients.